Research Analysts’ Weekly Ratings Changes for Vertex Pharmaceuticals (VRTX)

A number of research firms have changed their ratings and price targets for Vertex Pharmaceuticals (NASDAQ: VRTX):

• 11/3/2026 – Vertex Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $560.00 to $570.00. They now have an “overweight” rating on the stock.
• 11/3/2026 – Vertex Pharmaceuticals had its price target raised by Scotiabank from $558.00 to $660.00. They now have a “sector outperform” rating on the stock.
• 11/3/2026 – Vertex Pharmaceuticals had its price target lowered by Morgan Stanley from $665.00 to $660.00. They now have an “overweight” rating on the stock.
• 11/3/2026 – Vertex Pharmaceuticals had its price target raised by The Goldman Sachs Group from $654.00 to $725.00. They now have a “buy” rating on the stock.
• 11/3/2026 – Vertex Pharmaceuticals had its price target raised by UBS Group from $615.00 to $640.00. They now have a “buy” rating on the stock.
• 11/3/2026 – Vertex Pharmaceuticals had its price target raised by TD Cowen from $550.00 to $575.00. They now have a “buy” rating on the stock.
• 11/3/2026 – Vertex Pharmaceuticals had its price target raised by Royal Bank Of Canada from $576.00 to $600.00. They now have an “outperform” rating on the stock.
• 11/3/2026 – Vertex Pharmaceuticals had its price target raised by Wells Fargo & Company from $550.00 to $650.00. They now have an “overweight” rating on the stock.
• 11/3/2026 – Vertex Pharmaceuticals had its price target raised by Stifel Nicolaus from $500.00 to $563.00. They now have a “hold” rating on the stock.
• 11/3/2026 – Vertex Pharmaceuticals had its price target raised by Cantor Fitzgerald from $595.00 to $619.00. They now have an “overweight” rating on the stock.
• 10/31/2026 – Vertex Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/17/2026 – Vertex Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/16/2026 – Vertex Pharmaceuticals was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 10/8/2026 – Vertex Pharmaceuticals had its price target raised by Royal Bank Of Canada from $570.00 to $576.00. They now have an “outperform” rating on the stock.
• 10/2/2026 – Vertex Pharmaceuticals was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 9/28/2026 – Vertex Pharmaceuticals had its price target raised by UBS Group from $585.00 to $615.00. They now have a “buy” rating on the stock.
• 9/23/2026 – Vertex Pharmaceuticals had its price target raised by Jefferies Financial Group from $633.00 to $640.00. They now have a “buy” rating on the stock.
• 9/23/2026 – Vertex Pharmaceuticals had its price target raised by TD Cowen from $525.00 to $550.00. They now have a “buy” rating on the stock.
• 9/21/2026 – Vertex Pharmaceuticals is now covered by Leerink Partners. They set an “outperform” rating and a $594.00 price target on the stock.
• 9/11/2026 – Vertex Pharmaceuticals is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $560.00 price target on the stock.
• 9/10/2026 – Vertex Pharmaceuticals was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.

Vertex Pharmaceuticals Trading Up 2.6%

Shares of VRTX traded up $14.06 during trading hours on Wednesday, reaching $544.82. 451,890 shares of the stock traded hands, compared to its average volume of 1,389,704. Vertex Pharmaceuticals Incorporated has a 52-week low of $406.67 and a 52-week high of $568.67. The company’s 50-day moving average price is $522.98 and its two-hundred day moving average price is $480.37. The company has a market cap of $138.27 billion, a P/E ratio of 35.06, a price-to-earnings-growth ratio of 2.65 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 22.40% and a net margin of 30.70%. The firm had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the prior year, the company posted $4.80 EPS. The company’s quarterly revenue was up 11.8% on a year-over-year basis. On average, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.74 EPS for the current year.

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.